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TLR signaling in human antigen-presenting cells
regulates MR1-dependent activation of MAIT cells
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Mucosal-associated invariant T (MAIT) cells are an abundant innate-like T lymphocyte
population that are enriched in liver and mucosal tissues. They are restricted by MR1,
which presents antigens derived from a metabolic precursor of riboflavin synthesis, a
pathway present in many microbial species, including commensals. Therefore, MR1-
mediated MAIT cell activation must be tightly regulated to prevent inappropriate acti-
vation and immunopathology. Using an in vitro model of MR1-mediated activation of
primary human MAIT cells, we investigated the mechanisms by which it is regulated.
Uptake of intact bacteria by antigen presenting cells (APCs) into acidified endolysoso-
mal compartments was required for efficient MR1-mediated MAIT cell activation, while
stimulation with soluble ligand was inefficient. Consistent with this, little MR1 was seen
at the surface of human monocytic (THP1) and B-cell lines. Activation with a TLR ligand
increased the amount of MR1 at the surface of THP1 but not B-cell lines, suggesting differ-
ential regulation in different cell types. APC activation and NF-κB signaling were critical
for MR1-mediated MAIT cell activation. In primary cells, however, prolonged TLR signal-
ing led to downregulation of MR1-mediated MAIT cell activation. Overall, MR1-mediated
MAIT cell activation is a tightly regulated process, dependent on integration of innate
signals by APCs.
Keywords: Activation  Antigen presenting cell  Endotoxin tolerance  MAIT cells  MR1 
NF-κB
 Additional supporting information may be found in the online version of this article at thepublisher’s web-site
Introduction
Mucosal-associated invariant T (MAIT) cells are innate-like T
lymphocytes that are restricted by the non-classical MHC class
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Ib-related protein, MHC-related protein 1 (MR1) [1, 2]. MR1
is nonpolymorphic and highly evolutionarily conserved [3, 4].
MAIT cells predominantly express a canonical semi-invariant
T-cell receptor, Vα7.2-Jα33 [1, 5]; in addition minor populations
of MR1-restricted MAIT cells with Vα7.2-Jα12 and Vα7.2-Jα20
T-cell receptors have recently been described [6, 7]. MAIT cells
are abundant in humans, comprising 5% of T lymphocytes in
C© 2016 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co.
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adult blood, with up to 95% expressing CD8α [8, 9]. MAIT cells
are further enriched in the liver, where they comprise18% of all
lymphocytes [10], and are also found at mucosal sites [1].
MR1 has recently been shown to present a microbially
derived metabolic precursor of riboflavin biosynthesis [11, 12].
MR1 captures and binds unstable ribityllumazine intermediates
5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU)
and 5-(2-oxoethylideneamino)6-D-ribitylaminouracil (5-OE-RU),
which are formed by the condensation of 5-amino-6-D-
ribitylaminouracil (5-A-RU), an intermediate in riboflavin
biosynthesis, with methylgyoxal or glyoxal respectively [12].
5-OP-RU was found in the supernatant of a Salmonella sp.
culture and was able to activate MAIT cells [11, 12]. Consistent
with this, MAIT cells are activated by riboflavin-synthesizing
microorganisms in an MR1-dependent manner [13]. In addition,
MAIT cells can be activated by both riboflavin-synthesizing and
nonriboflavin-synthesizing bacterial species, independently of
TCR stimulation, by the pro-inflammatory cytokines, interleukin-
12 and interleukin-18 [14, 15].
Given the abundance of MAIT cells at mucosal surfaces and in
liver [1, 10], the wide range of microorganisms, including com-
mensals, that are able to produce the ligand for MR1 [13], the
small molecular size of the ligand [11, 12], which may encourage
diffusion, and the rapid response of MAIT cells to MR1-mediated
activation [14], we hypothesised that MR1-mediated MAIT cell
activation must be tightly regulated to prevent immunopathology
while ensuring activation in the setting of infection. To inves-
tigate this we used an in vitro model which we have recently
described which separates early MR1-mediated MAIT cell acti-
vation from later MR1-independent, IL-12 and IL-18-dependent,
activation [14]. In this paper we demonstrate that efficient MR1-
mediated MAIT cell activation requires uptake of intact bacteria
by antigen presenting cells (APCs), as well as activation of the APC
via NF-κB activation or interferon signaling. Furthermore, MR1-
mediated MAIT cell activation is negatively regulated in endotoxin
tolerance, suggesting tight regulation.
Results
Early activation of MAIT cells is MR1 dependent and
occurs independently of IL-12 and IL-18
We have previously shown that there are two mechanisms of
primary human MAIT cell activation: MR1-dependent activa-
tion (TCR-dependent), which occurs early, and IL-12- and IL-18-
mediated activation, which occurs later and is independent of TCR
signaling [14]. As THP1 cells were used as the APCs in the previous
experiments, we assessed whether these findings were generaliz-
able to other APC types. Primary human monocytes were incu-
bated overnight with fixed Escherichia coli [13, 14, 16] and CD8+
T cells were either added for the final 5 h of incubation (Fig. 1A–C)
or co-incubated overnight (Fig. 1D–F); MAIT cell activation was
detected by intracellular cytokine staining for IFN-γ production;
the gating strategy is shown in Supporting Information Fig. 1.
While the magnitude of responses was lower with primary human
monocytes than with THP1s (Fig. 1B and 1E), the experiment
confirmed that early MAIT cell activation (5-h co-incubation) was
MR1-dependent (Fig. 1C), while late MAIT cell activation (20-h
co-incubation) was dependent upon bothMR1 and IL-12 and IL-18
(Fig. 1F). The MR1 dependence of early MAIT cell activation was
confirmed using primary B cells (Supporting Information Fig. 2A
and B), or an EBV-transformed B-cell line (BCL) (Supporting Infor-
mation Fig. 2C and D) as APCs. Therefore early (5 h) production
of IFN-γ by MAIT cells can be used as a read-out of MR1-mediated
MAIT cell activation, irrespective of the APC.
Bacterial uptake into acidified endosomes is required
for efficient MR1-driven MAIT cell activation
The MAIT cell-activating MR1 ligand, 5-OP-RU, was recently iden-
tified from a Salmonella enterica subsp. enterica culture super-
natant [11, 12]. C1R.hMR1 cells, which express large amounts of
MR1 at the cell surface [17], efficiently activated MAIT cells when
treated with Salmonella sp. culture supernatant or the synthetic
ligand, rRL-6-CH2OH [11]. In contrast, in an earlier study the
activation of murine MAIT cells by E. coli infected bone marrow-
derived dendritic cells was dependent upon phagocytosis and
endosomal acidification [13]. Also, surface expression of MR1 in
nontransduced cells has been reported to be transient and dif-
ficult to detect [18]. Therefore, we hypothesized that nontrans-
duced APCs treated with bacterial culture supernatant would only
weakly stimulate MAIT cells.
To test this THP1s were treated with bacterial culture super-
natant, cell lysate, or fixed intact bacteria and their ability to stim-
ulate MAIT cells assessed; equivalent proportions of a stationary
phase culture were used. Robust MAIT cell activation was only
seen with intact bacteria. With both E. coli and non-typhoidal
Salmonella, weak activation was seen with both the supernatant
and cell lysate (Fig. 2A). Confirming the superior stimulatory abil-
ity of intact bacteria, robust MR1-mediated MAIT cell activation
was still seen with lower numbers of intact bacteria per APC (Sup-
porting Information Fig. 3A), while the response to supernatant
was rapidly lost (Supporting Information Fig. 3B). Primary human
monocyte-derived macrophages (MDMs) (Fig. 2B) and primary
human monocytes (Fig. 2C) treated with intact E. coli also stimu-
lated a more robust response from MAIT cells than those treated
with E. coli supernatant. Therefore, while the ligand is present in
culture supernatant, more robust MR1-mediated MAIT cell activa-
tion is seen with an equivalent amount of intact bacteria.
The robust stimulatory ability of THP1s treated with fixed
intact bacteria but not supernatant or bacterial cell lysate, sug-
gested that uptake of intact bacteria into the cell is important for
subsequent MAIT cell activation. Consistent with this, treatment
of THP1s with cytochalasin D, an inhibitor of actin polymeriza-
tion, partially inhibited the ability of THP1s treated with intact
E. coli to stimulate MAIT cells (Fig. 2D). Furthermore, inhibition
of endolysosomal acidification with bafilomcyin A1, an inhibitor
of the H+ ATPase pump, partially inhibited the ability of THP1s to
C© 2016 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 1. Early MAIT cell activation is MR1-
dependent and IL-12 plus IL-18-independent.
Primary human monocytes or THP1 cells were
incubated for 20 h with fixed E. coli. CD8+ T cells
(autologous to the monocytes) were either
(A–C) added for the final 5 h of culture, or (D–F)
co-cultured for the entire 20 h. (A, D) Block-
ing antibodies were added as indicated. (B, E)
Brefeldin A was added for the final 4 h of
culture. Cells were stained with fluorochrome-
labeled antibodies (anti-CD3-PECy7, anti-CD8-
eFluor450, anti-CD161-APC, anti-Vα7.2-PE) and
Live/Dead Fixable Near IR dye, and the per-
centage of MAIT cells making IFN-γ deter-
mined by intracellular cytokine staining (anti-
IFN-γ−FITC). (C, F) The effect of the blocking
antibodies on production of IFN-γ byMAIT cells,
normalized to the production of IFN-γ in the
absence of blocking antibodies, was assessed.
Data shown are pooled from 3 (C, E, F) or 4
(B) independent experiments. Means and each
data point, representing different donors, are
shown ((B) primary human monocytes, n = 12,
THP1 cells, n = 9; (C) primary human mono-
cytes, n = 7, THP1 cells, n = 6; (E, F) both cell
types, n = 8). Comparisons were made with
a repeated measures one-way ANOVA with
Dunnett’s multiple comparison test, compar-
ing all conditions to isotype. *p0.05, **p0.01,
***p0.001, ****p0.0001. See Supporting Infor-
mation Fig. 1 for the gating strategy.
activate MAIT cells (Fig. 2E). Neither inhibitor adversely effected
THP1 viability compared with DMSO (Supporting Information
Fig. 4A and 4C), although the relative proportion of nonadher-
ent cells recovered was reduced with cytochalasin D (Supporting
Information Fig. 4B) but not bafilomycin A (Supporting Informa-
tion Fig. 4D). Furthermore, neither inhibitor effected the stimula-
tion of MAIT cells by THP1 cells treated with E. coli supernatant
(Fig. 2F). While uptake of riboflavin-synthesizing bacteria led to
robust MAIT cell activation (Fig. 2A), induction of phagocytosis
with Enterococcus faecalis, which does not synthesize riboflavin,
did not enhance the MAIT cell stimulatory capacity of E. coli cul-
ture supernatant (Fig. 2G). Therefore, uptake of intact ligand-
producing bacteria into an acidic compartment is required for
efficient MR1-mediated antigen presentation.
C© 2016 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 2. Uptake of intact bacteria into an acidified endosomal compartment is required for efficient MR1-mediated MAIT cell activation. (A)
THP1 cells were incubated for 20 h with equivalent amounts of intact E. coli, E. coli cell lysate, E. coli culture supernatant, intact Salmonella,
Salmonella cell lysate, or Salmonella culture supernatant, then CD8+ T cells added for the final 5 h of culture and the production of IFN-γ by
MAIT cells determined; as THP1 cells were washed prior to the addition of CD8+ T –cells, supernatant and lysate were replaced. Data shown are
pooled from two independent experiments with eight different donors. (B) Primary human MDMs or (C) primary human monocytes (isolated by
fluorescence activated cell sorting) were incubated for 20 h with equivalent amounts of intact E. coli or E. coli supernatant, then CD8+ T cells added
for the final 5 h of culture and the production of IFN-γ by MAIT cells determined. (B, C) Pooled data from three independent experiments with
10 (B) or 6 (C) different donors is presented. (D) The effect of cytochalasin D and (E) bafilomycin A1, added at the start of culture, on the ability
of E. coli-treated APCs to subsequently stimulate IFN-γ production by MAIT cells was assessed. Six (D) and 7 (E) independent experiments were
performed with 11 (D) and 13 (E) different donors and pooled data are presented. (F) THP1 cells were incubated overnight with E. coli supernatant,
Enterococcus faecalis, or both, and IFN-γ production by MAIT cells at 5 h was assessed. Three independent experiments were performed with 12
different donors and pooled data are presented. In all experiments, THP1s/ MDMs/monocytes were washed three times prior to the addition of
CD8+ T cells (isolated with CD8 microbeads (A, B, D–F) or CD8-PE and anti-PE microbeads (C)) for the final 5 h of culture; brefeldin A was added
for the final 4 h. Cells were stained with fluorochrome-labeled antibodies ((A, B, D–F): anti-CD3-PECy7, anti-CD8-eFluor450, anti-CD161-APC, anti-
Vα7.2-PE; (C): anti-CD3-PECy7, anti-CD8-PE, anti-CD161-APC, anti-Vα7.2-FITC) and Live/Dead Fixable Near IR dye, and the percentage of MAIT cells
making IFN-γ determined by intracellular cytokine staining ((A, B, D–F): anti-IFN-γ−FITC; (C): anti-IFN-γ−PerCPCy5.5). Means and each data point,
representing different donors, are shown. Comparisons were made with repeated measures one-way ANOVA with Tukey’s multiple comparison
test when all conditions were compared with one another (A) or with Sidak’s multiple comparison test, when preselected pairs of columns were
compared (B–D). *p0.05, **p0.01, ***p0.001, ****p0.0001.
Surface expression of MR1 is differentially regulated
in different cell lines
The previous report of robust activation of MAIT cells by
Salmonella culture supernatant used C1R cells transduced with
MR1 (C1R.hMR1) as the APC [11]. C1R.hMR1 cells express high
levels of MR1 at the cell surface [17]. Therefore, we hypothesized
that the level of surface MR1 expression is critical for the ability
of an APC to present soluble ligand.
To address this question we derived two cell lines overexpress-
ing MR1: THP1.hMR1 and BCL.hMR1. Overexpression of MR1
was confirmed by detection of the C-terminal HA tag (Fig. 3A).
C© 2016 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 3. Regulation of MR1 surface expression. (A) Intracellular expression of the HA tag in THP1.hMR1 cells and BCL.hMR1 cells (black lines), with
the parental THP1 and BCL cells (gray shaded) shown for comparison. Cells were stained with Live/Dead Fixable Near IR dye, fixed, permeabilized,
and stained with anti-HA-PE. (B) Traditional surface stain of MR1 on unstimulated THP1 cells, THP1.hMR1 cells, BCL cells and BCL.hMR1 cells
(all black line) compared to isotype (gray shaded). Cells were stained with Live/Dead Fixable Near IR dye and anti-MR1-AlexaFluor488 or an
AlexaFluor488-labeled isotype control. (C) Traditional surface stain of MR1 on THP1, THP1.hMR1, BCL, and BCL.hMR1 cells after treatment with
E. coli for 6 h or 20 h (overnight (ON)), or without treatment. The shaded histogram is cells stained with the isotype control. Cells were stained with
Live/Dead Fixable Near IR dye and anti-MR1-AlexaFluor488 or an AlexaFluor488-labeled isotype control. (D) MR1 capture assay (incubation with
anti-MR1-AlexaFluor488 or AlexaFluor488-labeled isotype control for 4 h at 37°C) on THP1, THP1.hMR1, BCL, and BCL.hMR1 cells after treatment
with E. coli for 6 h or overnight, or without treatment. (E, F) MR1 capture assay on THP1.hMR1 cells after treatment with (E) E. coli supernatant or (F)
a TLR2 agonist (HKLM) for 6 h or overnight, or untreated. (G) MR1 capture assay on THP1.hMR1 cells pretreated overnight with IKK inhibitor VII or
DMSO, or untreated prior to treatment with E. coli for 6 h. Cells that were not exposed to E. coli are shown. (H) Geometric mean fluorescent intensity
(GeoMFI) of MR1 (capture assay) on the parental THP1 cell line after treatment with E. coli for 6 h or overnight. (A–G) Representative plots are shown;
experiments were performed independently at least twice in triplicate. (H) Each data point represents the mean of technical triplicates from one of
four independent experiments; the mean of the independent experiments is shown. Comparisons were made with a repeated measures one-way
ANOVA with Tukey’s multiple comparison test. *p0.05, **p0.01, ***p0.001, ****p0.0001.
In unstimulated cells MR1 could only be detected at the surface
of BCL.hMR1 cells; no surface expression could be detected on
THP1, THP1.hMR1, or BCL cells (Fig. 3B). This likely reflects the
higher expression levels of the MR1.HA transgene in BCL.hMR1
cells (Fig. 3A), probably due to variable transduction and the
nonclonal nature of the cell lines. In addition, the low levels of
surface expression in both cell lines could be due to the C-terminal
HA tag impeding MR1 trafficking.
To investigate whether treatment with bacteria affected the
surface expression of MR1, cells were treated for 6 h or overnight
C© 2016 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
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with fixed E. coli and the cell surface stained forMR1. No change in
surface expression of MR1 was seen in BCL.hMR1 cells (Fig. 3C).
In contrast, a small increase in MR1 surface expression was seen
in THP1.hMR1 cells, which was more evident after 6 h treat-
ment with E. coli than overnight. No MR1 surface expression was
detectable in the parental BCL and THP1 cell lines (Fig. 3C).
We hypothesized that MR1 might not be detectable by regu-
lar immunostaining of the cell surface due to trafficking to and
from the surface, with little present at the surface at any one
time. To detect MR1 that might be trafficking to and from the sur-
face, anti-MR1 antibody was added to the media for the final 4 h
of culture (MR1 capture assay). Specific staining with anti-MR1
was seen with all cell lines (Fig. 3D). Furthermore, upon treat-
ment with E. coli up-regulation of MR1 surface expression was
detected in THP1 and THP1.hMR1 cells but not BCL or BCL.hMR1
cells (Fig. 3D), despite the higher levels of intracellular MR1 in
the BCL.hMR1 cells (Fig. 3A). In THP1.hMR1 cells, this increase
occurred early (6 h) with decreased amounts of MR1 detected
at the cell surface with prolonged (overnight) incubation with
E. coli (Fig. 3D). Similar changes inMR1 expressionwere seenwith
E. coli culture supernatant (Fig. 3E), with a TLR2 agonist (heat-
killed Listeria monocytogenes, which lacks the riboflavin synthetic
pathway) (Fig. 3F) and with E. faecalis (Supporting Information
Fig. 5A), suggesting changes in surface expression were depen-
dent upon cellular activation and did not require the presence of
ligand. Using a conventional surface immunostain, no upregula-
tion of surface expression of MR1 was seen when THP1.hMR1
cells were treated with the TLR2 agonist (Supporting Information
Fig. 5B). To confirm the specificity of the MR1 capture assay on
TLR2-treated THP1.hMR1 cells, the parental un-transduced THP1
cell line was treatedwith TLR2 agonist overnight and theMR1 cap-
ture assay performed: no staining was seen, suggesting antibody
26.5 was indeed binding to MR1 on TLR2-treated THP1.hMR1
cells (Supporting Information Fig. 5C).
Consistent with a change inMR1 surface expression upon cellu-
lar activation, E. coli-induced upregulation could be blocked with
an inhibitor of the NF-κB signaling pathway (IKK inhibitor VII,
which inhibits the IKK complex) (Fig. 3G). Interestingly, inhibit-
ing NF-κB signaling also partially inhibited detection of MR1 at
the cell surface in BCL.hMR1 cells treated with E. coli (Support-
ing Information Fig. 5D) and in untreated BCL.hMR1 cells (Sup-
porting Information Fig. 5E), and completely inhibited detection
in untreated THP1.hMR1 cells (Supporting Information Fig. 5E).
These results suggest that NF-κB signaling is required even for
basal surface expression of MR1.
In untransduced THP1 cells, increased trafficking of MR1 to
the surface upon treatment with E. coli was also evident, with a
small increase in surface MR1 6 h after exposure, which further
increased with overnight incubation (Fig. 3D and 3H). This con-
trasted with the kinetics of surface MR1 expression in THP1.hMR1
cells, in which maximal surface expression was seen after 6 h and
declined with overnight incubation (Fig. 3D). Inhibition of NF-κB
signaling inhibited detection of MR1 at the cell surface of untrans-
duced THP1 cells treated with E. coli (Supporting Information
Fig. 5F). Upregulation of MR1 surface expression on MDMs was
also evident after overnight treatment with E. coli (Supporting
Information Fig. 5G).
Therefore, there is little MR1 at the surface of unstimulated
THP1 and BCL cells, even when overexpressed. Surface expression
is increased in THP1 cells, but not BCL cells, following exposure to
pathogen associatedmolecular patterns, and signaling via NF-κB is
required. Of note, treatment of THP1.hMR1 cells with cytochalasin
D had no effect on E. coli-induced upregulation of MR1 surface
expression (Supporting Information Fig. 5H).
MR1 expression level limits presentation of ligand
from supernatant but not from intact bacteria
To assess whether differences in MR1 surface expression affected
the ability of APCs to activate MAIT cells, MR1-overexpressing cell
lines (THP1.hMR1 and BCL.hMR1) or parental cell lines (THP1
and BCL) were treated for 7 h or overnight with either E. coli
culture supernatant or intact fixed E. coli. Purified CD8+ T cells
were co-incubated for the final 5 h of culture and IFN-γ produc-
tion assessed by intracellular cytokine staining (Fig. 4A). With
bacterial culture supernatant, MR1 overexpression increased the
ability of APCs to stimulate MAIT cells irrespective of the cell
line (Fig. 4B,C). The duration of incubation with supernatant
(7 h versus overnight) did not significantly affect the ability of
THP1, THP1.hMR1, or BCL.hMR1 cell lines to activate MAIT cells
(Fig. 4B,C); with the parental BCL cell line, greater MAIT cell acti-
vation was seen with shorter incubation, however the effect was
modest (Fig. 4C).
With intact E. coli there was no difference in the ability of
THP1.hMR1 and parental THP1 cell lines to stimulate MAIT cells
(Fig. 4D). BCL.hMR1 cells stimulated more MAIT cells than the
parental BCL cells at 7 h but not overnight (Fig. 4E). Strikingly,
with prolonged incubation with intact bacteria the ability of all
APCs to stimulate MAIT cells increased significantly (Fig. 4D
and 4E).
Therefore, the level of MR1 surface expression is limiting for
the presentation of ligand from supernatant but not from intact
bacteria. With intact bacteria, prolonged incubation markedly
increases the ability of APCs to stimulate MAIT cells.
APC activation in vitro increases MR1-mediated
MAIT cell activation
Given this delay for maximal MAIT cell stimulatory ability, we
hypothesized that APC activation is important for MAIT cell
stimulation. Therefore we investigated whether preactivation of
THP1s with TLR agonists could enhance their ability to stimulate
MAIT cells early after exposure to bacteria (7 h); THP1s have
been reported to express TLR1-10 [19]. THP1s were incubated
overnight with or without TLR agonists and the following morning
intact E. coliwas added. Two hours later the cells were extensively
washed and CD8+ T cells were added (Fig. 5A). Preincubationwith
agonists to TLR1, TLR2, or TLR6 enhanced the early MAIT cell
C© 2016 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 4. The effect of MR1 expression
and time on the MAIT cell stimulatory
capacity of APCs treated with super-
natant or intact bacteria. (A) APCs
were incubated for 7 h or for 20
h (overnight (ON)) with fixed intact
E. coli or E. coli supernatant, and
CD8+ T cells added for the final 5
h of incubation. Fresh E. coli super-
natant was added to the appropriate
wells along with the CD8+ T cells.
Cells were stained with fluorochrome-
labeled antibodies (anti-CD3-PECy7,
anti-CD8-eFluor450, anti-CD161-APC,
anti-Vα7.2-PE) and Live/Dead Fixable
Near IR dye, and the percentage of
MAIT cells making IFN-γ determined
by intracellular cytokine staining (anti-
IFN-γ−FITC). (B)MAIT cell activation by
THP1 or THP.hMR1 cells treated with
E. coli supernatant. (C)MAIT cell activa-
tion by BCL or BCL.hMR1 cells treated
with E. coli supernatant. (D) MAIT cell
activation by THP1 or THP.hMR1 cells
treated with intact E. coli. (E) MAIT cell
activation by BCL or BCL.hMR1 cells
treated with intact E. coli. All experi-
ments were performed independently
twice with eight different donors and
pooled data are presented. Means and
each data point, representing different
donors, are shown. Comparisons were
made by repeated measures one-way
ANOVA with Sidak’s multiple compar-
ison test. *p0.05, **p0.01, ***p0.001,
****p0.0001.
stimulatory capacity of THP1s (Fig. 5B). Similarly preincubation
of THP1s with either type I or type II interferons enhanced their
early MAIT cell stimulatory capacity (Figs. 5C and 5D). Consis-
tent with our previous findings [14] and with Fig. 1, overnight
incubation of THP1 cells with TLR2, TLR4, or IFN-γ alone did not
result in early (5 h) MAIT cell activation (Supporting Information
Fig. 6A and B), which is MR1-dependent. Therefore preactivation
of THP1s enhances their ability to activate MAIT cells early after
exposure to bacteria.
To confirm the importance of APC activation for MAIT cell
stimulation, we assessed the effect of blocking NF-κB signaling.
THP1 cells were incubated overnight with intact E. coli in the
presence of inhibitors of the NF-κB pathway (IKK inhibitor VII or
(5Z)-7-oxozeanolol, which inhibits transforming growth factor-β
C© 2016 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
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Figure 5. Preactivation of THP1 cells enhances their early stimulatory ability. (A) THP1 cells were preactivated overnight with one of (B) a panel
of TLR agonists, (C) interferon α, οr (D) interferon γ. Fixed intact E. coli was added the following morning and 2 h later the THP1s were washed
three times and CD8+ T cells added for the final 5 h of incubation; brefeldin A was added for the final 4 h. Cells were stained with fluorochrome-
labeled antibodies (anti-CD3-PECy7, anti-CD8-eFluor450, anti-CD161-APC, anti-Vα7.2-PE) and Live/Dead Fixable Near IR dye, and the percentage
of MAIT cells making IFN-γ determined by intracellular cytokine staining (anti-IFN-γ−FITC). Two (C), 3 (B), or 4 (D) independent experiments
were performed and pooled data are presented. Means and each data point, representing different donors, are shown ((B) n = 12; (C) n = 8; (D)
n = 15). Comparisons were made with repeated measures one-way ANOVA with Sidak’s multiple comparison test. *p0.05, **p0.01, ***p0.001,
****p0.0001.
activated kinase-1 (TAK1)) or DMSO. Cells were then thoroughly
washed and incubated with purified CD8+ T cells for 5 h. Inhibi-
tion of the NF-κB pathway potently inhibited the ability of THP1
cells to activate MAIT cells (Figs. 6A, and 6B). Both inhibitors
had a significant but minor (5%) negative effect on THP1 cell
viability; (5Z)-7-oxozeanolol, but not IKK inhibitor VII, had a sig-
nificant but minor (5.5%) negative impact on THP1 frequency
(Supporting Information Fig. 7A–D). Furthermore, treatment with
IKK inhibitor VII did not inhibit the ability of THP1 cells to phago-
cytose E. coli (Supporting Information Fig. 7E). Inhibition of THP1
activation was confirmed by immunophenotyping, with inhibition
of E. coli-induced upregulation of the activation markers CD54,
CD80, CD86, HLAA2, andHLADR (Supporting Information Fig. 8).
Similar results were obtained with BCL.hMR1 cells treated with
intact E. coli (Fig. 6C) and BCL.hMR1 cells treated with E. coli
culture supernatant (Fig. 6D). This suggests that not only is NF-κB
signaling important for surface expression of MR1 (Fig. 3G, Sup-
porting Information Fig. 5), it is also essential for the ability of the
APC to stimulate MAIT cells.
MAIT cell stimulation by MDMs and monocytes
depends on NF-κB signaling but is inhibited by LPS
Finally, the requirement for APC activation and the kinetics of
MR1-mediated MAIT cell activation were assessed using primary
human MDMs and monocytes. Consistent with the findings with
THP1s, the MAIT cell stimulatory ability of MDMs and mono-
cytes was dependent upon NF-κB signaling (Fig. 7A, Supporting
Information Fig. 9A); inhibition of NF-κB signaling did not affect
the ability of MDMs to phagocytose bacteria (Supporting Infor-
mation Fig. 10A). In contrast to THP1s, robust MAIT cell activa-
tion was seen early after exposure of MDMs to E. coli (7 h) and
significantly decreased with prolonged exposure (20 h) (Fig. 7B),
despite detectable surface expression of MR1 by MDMs after 20 h
(Supporting Information Fig. 10B). With monocytes there was a
small but significant increase in MAIT cell activation when mono-
cytes were exposed to E. coli for 20 h (Supporting Information
Fig. 9B); surface expression of MR1 was not detectable in mono-
cytes, even after treatment with E. coli (data not shown).
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Figure 6. Inhibition of NF-κB signaling in the APC inhibits MAIT cell activation. (A, B) Inhibition of MAIT cell activation by THP1 cells treated for
20 h (overnight, ON) with intact E. coli with or without (A) IKK inhibitor VII or DMSO or (B) (5Z)-7-oxozeanolol or DMSO. (C) Inhibition of MAIT cell
activation by BCL.hMR1 cells treated overnight with intact E. coli with or without IKK inhibitor VII or DMSO. (D) Inhibition of MAIT cell activation
by BCL.hMR1 cells treated overnight with E. coli supernatant with or without IKK inhibitor VII or DMSO. In all experiments, APCs were washed
three times and CD8+ T cells added for the final 5 h of culture; brefeldin A was added for the final 4 h. Cells were stained with fluorochrome-
labeled antibodies (anti-CD3-PECy7, anti-CD8-eFluor450, anti-CD161-APC, anti-Vα7.2-PE) and Live/Dead Fixable Near IR dye, and the percentage of
MAIT cells making IFN-γ determined by intracellular cytokine staining (anti-IFN-γ−FITC). All experiments were performed independently twice
and pooled data are presented. Means and each data point, representing different donors, are shown ((A) n = 8; (B) n = 8; (C) n = 7; (D) n = 6).
Comparisons were made with repeated measures one-way ANOVA with Dunnett’s multiple comparison test, with comparison to DMSO. *p0.05,
**p0.01, ***p0.001, ****p0.0001.
Figure 7. Regulation of MR1-mediated MAIT cell activation by monocyte-derived macrophages. (A) Ability of monocyte-derived macrophages
(MDMs) treated for 20 h with intact E. coli, with or without DMSO or IKK inhibitor VII, to stimulate IFN-γ production by MAIT cells. (B) Ability of
MDMs treated with intact E. coli for 7 h or for 20 h to stimulate IFN-γ production byMAIT cells. (C) Ability of MDMs preactivated with TLR agonists or
interferons to activate MAIT cells upon subsequent exposure to E. coli for 7 h. (D) Ability of MDMs preactivated with various concentrations of LPS
to activate MAIT cells upon subsequent exposure to E. coli for 7 h. In all experiments MDMs were washed three times prior to the addition of CD8+
T cells for the final 5 h of culture; brefeldin A was added for the final 4 h. Cells were stained with fluorochrome-labeled antibodies (anti-CD3-PECy7,
anti-CD8-eFluor450, anti-CD161-APC, anti-Vα7.2-PE) and Live/Dead Fixable Near IR dye, and the percentage of MAIT cells making IFN-γ determined
by intracellular cytokine staining (anti-IFN-γ−FITC). All experiments were performed independently twice and pooled data are presented. Means
and each data point, representing different donors, are shown ((A) n = 8; (B) n = 8; (C) n = 8; (D) n = 7). Comparisons were made by repeated
measures one-way ANOVA with Dunnett’s multiple comparison test (A), Tukey’s multiple comparison test (B), or Sidak’s multiple comparison test
(C, D). *p0.05, **p0.01, ***p0.001, ****p0.0001.
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Preactivation of MDMswith TLR agonists or type I or II interfer-
ons failed to enhance their ability to stimulateMAIT cells (Fig. 7C);
instead, preactivation of MDMs with the TLR4 agonist, LPS, signif-
icantly suppressed subsequent MAIT cell activation; there was also
a trend to decreased MAIT cell stimulation following preactivation
with TLR2, TLR3, or TLR5 agonists (Fig. 7C). Similarly, preacti-
vation of monocytes with LPS reduced their ability to stimulate
MAIT cells (Supporting Information Fig. 9C).
Pretreatment of monocytes and macrophages with LPS
can inhibit function through endotoxin tolerance [20–22] and
activation-induced cell death [23], although M-CSF-derived
human macrophages, as used here, are relatively resistant to
activation-induced cell death [24]. Endotoxin tolerance is defined
as hyporesponsiveness upon rechallenge with LPS. Suppression of
MHC class II antigen presentation in endotoxin tolerant mono-
cytes has previously been reported [25]. To address whether
MR1-mediated stimulation of MAIT cells was suppressed when
MDMs had previously been exposed to LPS,MDMswere pretreated
overnight with various concentrations of LPS and their ability to
stimulate MAIT cells subsequently assessed. Robust suppression
of MAIT cell stimulation was seen with as little as 10 ng/mL of
LPS (Fig. 7D); across all concentrations of LPS, a 62% (range 46–
78%) reduction in IFN-γ-production by MAIT cells was observed.
This could be partially explained by activation-induced cell death
of MDMs: the viability of MDMs exposed to LPS was reduced
by 23% (range 9–33%) (Supporting Information Fig. 10C). Fol-
lowing LPS exposure, MDMs retained their ability to phagocytose
bacteria (Supporting Information Fig. 10D), but produced less
TNF-α (52% reduction, range 39–62%) upon subsequent expo-
sure to E. coli (Supporting Information Fig. 9D), suggesting that
the remaining MDMs were endotoxin tolerant. Decreased TNF-α
production was also seen following pretreatment with HKLM (a
TLR2 agonist) (48% reduction, range 41–60%) but not Pam3CSK4
(a TLR1 agonist) (Supporting Information Fig. 10A), correlating
with the ability of MDMs to stimulate MAIT cells (Fig. 7C). When
monocytes were pre-exposed to LPS, a 38% reduction (range 19–
59%) in IFN-γ production byMAIT cells was observed (Supporting
Information Fig. 9C); there was no evidence of activation induced
cell death (Supporting Information Fig. 9D,E). Therefore, MR1-
mediated MAIT cell activation by primary human MDMs and
monocytes is also dependent upon NF-κB signaling, but is neg-
atively regulated upon prolonged exposure to endotoxin by endo-
toxin tolerance ± activation induced cell death.
Discussion
We have shown that MR1-mediated MAIT cell activation is tightly
regulated. Using an MR1-dependent model of MAIT cell activation
we have found that (i) uptake and processing of intact bacteria by
APCs leads to more robust MAIT cell activation than exposure to
soluble ligand, (ii) for soluble ligand the amount of MR1 at the
cell surface is rate-limiting, (iii) little MR1 is expressed at the cell
surface at any one time but that it traffics to and from the cell
surface, (iv) the rate at which MR1 accumulates at the cell surface
is increased upon APC activation and that this is dependent upon
NF-κB signaling, (v) MAIT cell stimulatory ability is dependent
upon NF-κB signaling and APC activation, and (vi) in MDMs and
monocytes MR1-mediated MAIT cell activation is negatively regu-
lated in endotoxin tolerance. We propose that these mechanisms
combine to regulate MR1-mediated MAIT cell activation.
MAIT cells can be activated with or without TCR activation.
Consistent with our recent reports [14, 15], we found that early
MAIT cell activation by E. coli-treated primary human monocytes
and B cells was MR1-dependent and IL-12+IL-18-independent,
while later activation involved both mechanisms. By restricting
observations to the early time-point it allowed us to specifically
investigate MR1-mediated antigen presentation. Furthermore, it
highlights the importance of considering cytokine-mediated acti-
vation when overnight cultures of MAIT cells are performed.
The MR1 ligand was recently identified as unstable ribityl-
lumazine intermediates 5-OP-RU and 5-OE-RU, which are
formed by condensation of 5-A-RU with methylgyoxal or gly-
oxal, respectively [11, 12]. 5-OP-RU was found in the super-
natant of a Salmonella culture and, when co-incubated with
C1R cells transduced with MR1, activated MAIT cells [11, 12].
However, given the number of commensal bacterial strains
that can synthesize riboflavin (http://www.genome.jp/kegg/
pathway/map/map00740.html), the lowmolecular weight of 5-A-
RU and ribityllumazine intermediates, and the potential for these
compounds to diffuse away from the site of infection (or even
to cross mucosal barriers), we hypothesized that MR1-mediated
MAIT cell activation must be tightly regulated to prevent inappro-
priate activation and subsequent immunopathology. Using non-
transduced THP1 cells we found that intact bacteria activate
MAIT cells substantially more efficiently than bacterial culture
supernatant. While the E. coli culture supernatant appears to con-
tain ligand, only weak MR1-mediated activation was seen. This
was not due to a difference between bacterial species, as simi-
lar results were obtained with non-typhoidal Salmonella. Further-
more, it would seem unlikely that there are higher concentrations
of the ligand in the bacterium than in the supernatant as little or no
stimulation was seen with bacterial cell lysate (although destruc-
tion during sonication cannot be excluded). Therefore, loading
of MR1 appears to occur most efficiently in an acidified endo-
somal compartment, and uptake of intact bacteria is the most
efficient means of delivering ligand to this compartment. This is
consistent with previous studies which have shown MR1 to be in
endolysosomes [26] and MR1-mediated MAIT cell activation to
be dependent upon endosomal acidification [13].
It is unclear why the induction of phagocytosis with intact Ente-
rococcus faecalis failed to enhance the MR1-mediated MAIT cell
stimulatory ability of E. coli supernatant. It may be that insufficient
soluble ligand was phagocytosed with the intact bacteria. Alterna-
tively, the formation of ribityllumazine derivatives 5-OP-RU and
5-OE-RU, through the condensation of bacterially derived 5-A-RU
with methylglyoxal or glyoxal respectively, may occur more effi-
ciently in the phagolysosome. Indeed, addition of 5-ARU alone
to C1R.MR1 cells was sufficient to increase surface expression of
MR1 and to activate Jurkat.MAIT cells [12]. Of note however, the
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ribityllumazine derivatives are less stable at <pH6 [12]. Alterna-
tively, the failure to complement E. coli supernatant with intact
E. faecalis could be due to differences in TLR signaling induced by
E. coli and E. faecalis, affecting THP1 phenotype and function, for
example the expression of co-stimulatory molecules. TLR signal-
ing differs in response to gram-negative and gram-positive bac-
teria [27]. While E. faecalis stimulates TLR2 [28], it stimulates a
less robust pro-inflammatory response by monocyte-derived den-
dritic cells than E. coli [29]. Enterococcus faecalis does however
stimulate sufficient IL-12 and IL-18 production by THP1 cells to
stimulate MAIT cells [14]. Differences in TLR signaling could also
contribute to the observed difference between intact E. coli and
E. coli supernatant. E. coli supernatant, however, is known to con-
tain multiple TLR agonists, including LPS, the TLR 5 agonist flag-
ellin, and a TLR2 agonist [30–32], and no difference was observed
in the upregulation of activation markers (data not shown) or of
surface expression of MR1 (Fig. 3D, 3E) between THP1s treated
with intact E. coli and E. coli supernatant.
We hypothesized the discrepancy in the stimulatory ability of
bacterial culture supernatant between our study and that of Kjer-
Nielsen et al. [11] may be due to the levels of MR1 available at
the cell surface. Indeed, the C1R.hMR1 cells used by Kjer-Nieslen
et al. constitutively express large amounts of MR1 at the cell sur-
face [17]. In contrast, untransduced THP1s and BCLs expressed
barely detectable levels of MR1 at the surface, even though mRNA
could be readily detected in THP1s (data not shown). This is
consistent with previous studies that have suggested that MR1
is ubiquitously expressed at the mRNA level [3, 33], but that sur-
face expression is difficult to detect [18]. Even when MR1 was
overexpressed in THP1 cells and BCLs, only a small amount of
MR1 was seen at the surface at any one time. This may reflect
the relatively low levels of intracellular hMR1.HA seen in these
nonclonal cell lines. In addition, it is possible that the C-terminal
HA tag interferes with MR1 trafficking. The increased staining
that was observed when anti-MR1 was added to the culture media
for 4 h suggests that there is turnover of MR1 at the surface.
Strikingly, this turnover was markedly increased in THP1s, but
not in BCLs, upon activation. This increased turnover of MR1 at
the cell surface was independent of ligand but dependent upon
activation and NF-κB signaling. Furthermore, it decreased with
prolonged activation. Increased transcription of MR1 was seen
in THP1 cells upon activation. Therefore, in THP1 cells surface
expression of MR1 is increased upon activation. In contrast, in
BCL cells, which are similar to C1R cells, increased levels of MR1
were seen at the surface and expression was unaffected by acti-
vation. Whether the higher level of MR1 surface expression seen
in C1R.MR1 cells compared with BCL.MR1 cells is due to a lack
of competition for β2-microglobulin by MHC class I molecules in
C1R cells remains to be determined. In unactivated THP1s and
BCLs, inhibition of NF-κB signaling reduced MR1 trafficking, sug-
gesting basal NF-κB signaling may indeed be important. Transient
trafficking ofMR1 to the cell surface ofmurine double-positive thy-
mocytes, B cells, macrophages, and dendritic cells has previously
been reported [18]. Surface expression of MR1 has also previously
been seen in the lung epithelial cell line, A549 after infection with
Mycobacterium tuberculosis [34]. Future studies should address
whether MR1 trafficking is similarly regulated in epithelial cells
and monocytes/macrophages.
NF-κB-signaling in the APC was required for MR1-mediated
MAIT cell activation. While NF-κB signaling affects MR1 traffick-
ing, NF-κB-mediated up-regulation of other molecules, such as
co-stimulatory molecules, or secretion of cytokines, may also be
required for robust MAIT cell-mediated activation. Indeed, Turtle
et al. [35] found that TCR signaling was detuned in MAIT cells and
that co-stimulation or pro-inflammatory cytokines were required
for robust MAIT cell responses to TCR stimulation. Consistent with
a requirement for APC activation, we found that preactivation
of THP1 cells with TLR agonists or interferons enhanced MR1-
mediated MAIT cell activation. That type I or II interferons also
enhanced MR1-mediated MAIT cell activation, suggests that acti-
vation of APCs by pathways other than NF-κB signaling may also
enhance MR1-mediated activation. Activation of MAIT cells by
MDMs and primary human monocytes was also dependent upon
NF-κB signaling, However, in contrast to THP1s, MDMs robustly
activated MAIT cells early after exposure to bacteria with a later
reduction, while in the case of primary human monocytes there
was only a small increase in stimulatory ability with prolonged
exposure to bacteria. With both MDMs and monocytes preactiva-
tion did not enhance MAIT cell activation. This suggests that in
contrast to monocytic THP1s, all the proteins required for efficient
processing of ligand from intact bacteria, presentation by MR1,
and co-stimulation, are already expressed by MDMs and primary
human monocytes.
This is consistent with a hypothesis whereby sensing of
pathogen-associated molecular patterns by pattern recognition
receptors, such as TLRs, is required to license the APC to acti-
vate MAIT cells via MR1. While Le Bourhis et al. previously
found that mouse bone marrow-derived dendritic cells knocked
out for MyD88 or TRIF showed only a modest decrease in
MAIT cell stimulatory ability [13], cytokine-mediated MAIT cell
activation by IL-12 and IL-18 was not excluded in these exper-
iments. In addition, redundancy in pathways for APC activation
upon exposure to bacteria may also contribute to these differing
results.
MR1-mediated MAIT cell activation by MDMs was also sig-
nificantly negatively regulated by pretreatment with LPS. Pre-
treatment with TLR2, TLR3, and TLR5 agonists also appeared
to negatively regulate MAIT cell activation, although this did not
reach significance. The suppressive effect of TLR4 was partially
explained by decreased viability of LPS-treated MDMs, however
the significant decrease in TNF-α production upon restimulation
and the preservation of phagocytic function suggested that endo-
toxin tolerance also contributed to the inhibition of MAIT cell
activation [36]. Endotoxin tolerance was more evident in primary
monocytes, where LPS pretreatment suppressed their ability to
subsequently activate MAIT cells, but had no effect on mono-
cyte viability. This combination of activation-induced cell death
and endotoxin tolerance may also explain the decreased stimula-
tory capacity of MDMs with prolonged exposure to bacteria. It is
unclear why MDMs were more sensitive to the suppressive effects
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of LPS than THP1s. Pretreatment of THP1 cells with LPS did how-
ever fail to enhance the early activation of MAIT cells (Fig. 5B),
despite the ability of THP1 cells to respond to LPS [14].
Activation-induced cell death and endotoxin tolerance have
both been suggested to be negative feedback mechanisms to
prevent over-activation in the presence of on-going TLR stimu-
lus [37, 38]. MHC class II surface expression and MHC class II-
mediated CD4+ T-cell activation have previously been shown to be
negatively regulated by endotoxin tolerance [25]. Here we have
shown that endotoxin tolerance also negatively regulates both
MR1 surface expression and MR1-mediated MAIT cell activation.
Given that MR1 presents a microbially derived ligand, downreg-
ulation upon prolonged exposure to LPS would limit MAIT cell
over-activation in the face of persisting infection.
In conclusion, we have shown that MR1-mediated MAIT cell
activation is tightly regulated at several levels. Efficient MR1-
mediated MAIT cell activation requires both intact bacteria to
access an acidified endolysomal compartment and activation of
the APC through NF-κB or interferon signaling pathways. Fur-
thermore, MR1-mediated MAIT cell activation is negatively reg-
ulated upon prolonged TLR stimulation. We propose that these
mechanisms combine to prevent inappropriate or prolonged MR1-
mediated activation, which could otherwise cause immunopathol-
ogy. These findings have implications for the development of
MAIT cell based immunotherapies.
Materials and methods
General
These studies were conducted in a laboratory that operates under
exploratory research principles and were performed using inves-
tigative protocols and assays. The raw data are provided in a
supplementary file.
Cells
Peripheral blood mononuclear cells (PBMCs) were isolated from
leukocyte cones from the NHS Blood Bank or from blood from
healthy donors (collected with informed consent with approval
from the University of Otago Human Ethics Committee (Health))
using Lymphoprep (Axis-Shield, Dundee, UK). PBMCs were
cryopreserved in freezing media (90% fetal calf serum (FCS),
10% DMSO (both Sigma-Aldrich, Dorset, UK)), and stored in
liquid nitrogen. Frozen PBMCs were thawed immediately prior
to isolation of CD8+ T cells, B cells, or monocytes, and were
washed in RPMI 1640 media supplemented with 10% FCS,
L-glutamine, and penicillin/streptomycin (R10) (all Sigma-
Aldrich) with (20 μg/mL) DNAse (Roche, Mannheim, Germany).
CD8+ T cells were isolated with CD8 microbeads or, where
indicated in the figure legend, with anti-PE microbeads (Miltenyi
Biotec, Surrey, UK) as per the manufacturer’s instructions.
Primary human monocytes or B cells were isolated with CD14
or CD19 microbeads respectively (Miltenyi Biotec); in some
experiments, where indicated in the figure legend, monocytes
were sorted on a FACS Aria (BD Biosciences, San Jose, CA,
USA). Monocyte-derived macrophages were derived by culturing
primary human monocytes in 50 ng/mL M-CSF (R&D Systems,
Abingdon, UK) for 6–7 days. THP1 cells (ECACC, Wiltshire, UK)
were cultured in R10 + 0.05 mM 2-mercaptoethanol (Sigma-
Aldrich). An EBV-transformed B-cell line (kindly provided by
Dr Henrik Kloverpris, University of Oxford, UK [39]) was cultured
in R10. The 293Ta lentiviral packaging cell line (GeneCopoeia,
Rockville, MD, USA) was maintained in DMEM (Sigma-Aldrich) +
10% FCS + penicillin/streptomycin.
Inhibitors, TLR agonists, cytokines, and
functional antibodies
The following inhibitors were used: cytochalasin D (Sigma-
Aldrich) 5 μg/mL; bafilomycin A1 (Sigma-Aldrich) 10 nM; IKK
inhibitor VII (Merck-Millipore, Darmstadt, Germany) 5 μM; (5Z)-
7-oxozeaenol (Tocris, Bristol, UK) 0.75μM. The effect of inhibitors
on THP1 cell viability is shown in Supplementary Fig. 4. The
following TLR agonists were used at 1 μg/mL unless otherwise
indicated: Pam3CSK4, HKLM, Poly(I:C), LPS E. coli K12, flagellin
Salmonella Typhimurium, FSL-1, Imiquimod, ssRNA40/Lyovec,
and ODN2006 (all InvivoGen, San Diego, CA, USA). The follow-
ing cytokines were used: M-CSF (R&D Systems) 50 ng/mL; IFN-γ
(Miltenyi Biotec) 1000 U/mL; interferon-α2a (Miltenyi Biotec)
1000 U/mL. The following blocking antibodies were used: anti-
MR1 (clone 26.5; TH) 10 μg/mL; anti-IL-12p40/70 (eBioscience,
Hatfield, UK) 5 μg/mL; anti-IL-18 (MBL International, Woburn,
MA, USA) 5 μg/mL.
Antibodies
The following antibodies were used: Vα7.2-PE, Vα7.2-FITC, CD3-
PECy7, CD8-PE, CD14-AF488, CD80-PECy7, CD86-PerCPCy5.5,
HLA-A2-PE, HLA-DR-FITC, IFN-γ-PerCPCy5.5 (Biolegend, Lon-
don, UK), CD161-APC, IFN-γ-FITC, HA-PE (Miltenyi Biotec), CD8-
eFluor450, CD54-APC (eBioscience). Samples were stained with
Live/Dead Fixable Near IR dye (Invitrogen, Paisley, UK). Anti-
MR1 antibody (clone 26.5) and an isotype control (IgG2A, R&D
Systems) were labeled with an AlexaFluor488-conjugated anti-
mouse IgG Fab fragment (Jackson ImmunoResearch, West Grove,
PA, USA), as previously described [40, 41]. The reaction was
quenched with normal mouse immunoglobulin (Sigma-Aldrich).
In some experiments, where indicated in the figure legend, anti-
MR1-PE (clone 26.5) and an IgG2A-PE isotype control were used
(both Biolegend).
Bacteria
E. coli (DH5α), non-typhoidal Salmonella, or Enterococcus fae-
calis (clinical isolates obtained from the Microbiology Laboratory,
John Radcliffe Hospital, Oxford) were grown overnight in Luria
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broth (Sigma-Aldrich). Bacteria were washed twice in phosphate
buffered saline (PBS), then fixed for 20 min at room tempera-
ture in 2% paraformaldehyde/PBS. After fixation, bacteria were
washed two times and resuspended in PBS. Bacterial stocks were
quantified by flow cytometry using the MACSQuant. Each batch
was standardized to the previous batch. Bacteria were added at
25 bacteria/APC unless otherwise indicated.
Bacterial cell lysates were prepared by sonication (6 × 30 s
pulses at 15 μm using an MSE Soniprep 150 (Sanyo Gallenkamp
PLC, Leicester, UK)). The resulting lysate was filtered through a
0.2 μm filter prior to use. Bacterial supernatant was prepared
by centrifugation of an overnight culture, followed by filtration
through a 0.2 μm filter. Ten microliters of bacterial cell lysate
or supernatant were added unless otherwise indicated; this was
equivalent to 2× 106 bacteria (25 bacteria/APC) or the equivalent
proportion of the culture supernatant. Bacterial cell lysate and
supernatant were freshly prepared for each experiment.
Generation of THP1.hMR1 and BCL.hMR1
The plasmid, pLV120.hMR1-HA, encoding human MR1 with a
C-terminal 3x HA tag under the control of a CMV promoter
and puromycin resistance, was synthesized by GeneCopoeia
(EX-W1295-Lv120). pLV120.hMR1-HA was maintained in GCI-L3
chemically competent cells (GeneCopoeia). The lentiviral vector
was produced by co-transfection of pLV120.hMR1-HA and Lenti-
Pac HIV mix into 293Ta lentiviral packaging cells with EndoFectin
Lenti transfection reagent (all GeneCopoeia). After overnight incu-
bation, media were replaced with fresh DMEM+5% FBS supple-
mented with 1:500 TitreBoost reagent (Genecopoeia). Lentiviral-
containing supernatant was harvested 2 days post-transfection,
centrifuged, and filtered. Lentiviral supernatants were mixed with
Lenti-Pac concentration solution (GeneCopoeia,) and incubated
overnight at 4°C. The solution was centrifuged at 3500 × g for
25 min at 4°C, the supernatant discarded, and the virus pellet
resuspended in PBS. Lentiviral vectors were stored at −80°C prior
to use.
THP1 and BCL lines overexpressing hMR1.HA were generated
by infection with the lentiviral vector. Cells were resuspended in
media containing 8 μg/mL polybrene (Sigma-Aldrich). Virus was
added and cells centrifuged at 2250 rpm for 30min. Selection with
puromycin-containing media (4 μg/mL) was initiated 24 h post-
infection. Transgene expressionwas determined by flow cytometry
for both HA tag and MR1.
MAIT cell activation
APCs were seeded at 8 × 104/well in U-bottomed (or flat-
bottomed for monocyte-derived macrophages) 96-well plates;
viable cells were counted using Trypan Blue (Invitrogen) and a
Neubauer counting chamber. APCs were incubated overnight for
20 h. Fixed bacteria (25 bacteria per cell unless otherwise stated),
bacterial cell lysate, or bacterial culture supernatant (both 10
μL unless otherwise stated) were added at the start of culture
or, in some experiments, for the final 7 h of culture. In some
experiments pharmacological inhibitors, TLR agonists, interferon-
α or IFN-γ, were added at the start of culture as indicated. CD8+
T cells were added at 1–2 × 105/well either at the start of culture
(total 20 h co-culture) or for the final 5 h (total 5 h co-culture);
blocking antibodies were added at the same time as the CD8+
T cells. When CD8+ T cells were added for the final 5 h of cul-
ture, APCs were washed three times in R10 before the addition of
the CD8+ T cells. Brefeldin A (3 μg/mL) was added for the final
4 h of culture. Cells were analyzed for IFN-γ production by intra-
cellular cytokine staining.
Measurement of phagocytosis
Phagocytosis was measured with the pHrodo R© Red E. coli
BioParticles R© Phagocytosis Kit for Flow Cytometry (Thermo Fisher
Scientific, Waltham, MA, USA) as per the manufacturer’s proto-
col. Monocyte-derived macrophages were detached by pipetting
following a 30-min incubation on ice in PBS + 5 mM EDTA and
12 mM lidocaine (both Sigma-Aldrich).
Immunostaining
Immunostaining was performed as previously described [16].
Briefly, samples were stained with antibodies against CD3, CD8,
CD161, and Vα7.2, and with Live/Dead Fixable Near IR dye for 20
min at 4°C, then washed, then fixed for 20 min in 2% formalde-
hyde at 4°C, then washed in 1× Permeabilization Buffer (eBio-
science) prior to staining with an antibody against IFN-γ, and
restaining CD3, CD8, CD161, and Vα7.2.
To stain for MR1, pre-labeled anti-MR1 (or isotype control)
was added at 10 μg/mL for the final 4 h of culture. Cells were
then washed, stained with Live/Dead Fixable Near IR dye, and
fixed, prior to analysis by flow cytometry.
Flow cytometry
Flow cytometry was performed on aMACSQuant (Miltenyi Biotec)
or a FACS Canto (BD Biosciences). Samples were gated on
lymphocytes/alive/CD3+CD8+/CD161++Vα7.2+ cells (Support-
ing Information Fig. 1). Analysis was performed in FlowJo 9.6
(TreeStar, Ashland, OR, USA). The gate for IFN-γ positivity was
defined from the unstimulated sample.
Statistical analysis
Data were analyzed in GraphPad Prism software Version 6.0b
(La Jolla, CA, USA). Unless otherwise indicated, means and all
data points are shown. Comparisons between groups were made
by repeated measures one-way ANOVA followed by Dunnett’s,
C© 2016 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Tukey’s, or Sidak’s multiple comparison test, as indicated in the fig-
ure legends. Comparisons between two groups were made with a
Wilcoxon matched pairs signed rank test. Significance was defined
as p < 0.05. Where statistical model assumptions were poten-
tially not satisfied, alternative strategies (including transforma-
tions and nonparametric analyses, and sensitivity analyses with
possible leverage points removed) were investigated to ensure
that the reported interpretation of results was robust.
Acknowledgements: This work was supported by the Well-
come Trust (PK; WT091663MA), NIHR Biomedical Research Cen-
tre, Oxford, NIH U19AI082630, Oxford Martin School, and the
Oxford Dominions Trust (J.E.U.). J.E.U., C.W., R.P., and P.K.
designed the study. J.E.U., B.vW., R.F.H., K.R., P.P., and A.K. per-
formed the experiments and J.E.U., B.vW., R.F.H., K.R., and P.P.
analyzed data. T.H. provided a critical reagent. All authors were
involved in the preparation of the manuscript. We would like to
thankMr Andrew Gray, a biostatistician at the University of Otago,
for statistical review of our analyses.
Conflict of interest: The authors declare no commercial or finan-
cial conflict of interest.
References
1 Treiner, E., Duban, L., Bahram, S., Radosavljevic, M., Wanner, V., Tilloy,
F., Affaticati, P. et al., Selection of evolutionarily conserved mucosal-
associated invariant T cells by MR1. Nature 2003. 422: 164–169.
2 Huang, S., Gilfillan, S., Cella, M., Miley, M. J., Lantz, O., Lybarger, L.,
Fremont, D. H. et al., Evidence for MR1 antigen presentation to mucosal-
associated invariant T cells. J Biol Chem 2005. 280: 21183–21193.
3 Hashimoto, K., Hirai, M. and Kurosawa, Y., A gene outside the human
MHC related to classical HLA class I genes. Science 1995. 269: 693–695.
4 Parra-Cuadrado, J. F., Navarro, P., Mirones, I., Setie´n, F., Oteo, M. and
Martı´nez-Naves, E., A study on the polymorphism of human MHC class
I-related MR1 gene and identification of an MR1-like pseudogene. Tissue
Antigens 2000. 56: 170–172.
5 Tilloy, F., Treiner, E., Park, S.-H., Garcia, C., Lemonnier, F., de la Salle,
H., Bendelac, A. et al., An invariant T cell receptor α chain defines a novel
TAP-independent major histocompatibility complex class Ib–restricted
α/β T cell subpopulation in mammals. J Exp Med 1999. 189: 1907–1921.
6 Reantragoon, R., Corbett, A. J., Sakala, I. G., Gherardin, N. A., Furness,
J. B., Chen, Z., Eckle, S. B. G. et al., Antigen-loaded MR1 tetramers define
T cell receptor heterogeneity in mucosal-associated invariant T cells. J
Exp Med 2013. 210: 2305–2320.
7 Lepore, M., Kalinichenko, A., Colone, A., Paleja, B., Singhal, A., Tschumi,
A., Lee, B. et al., Parallel T-cell cloning and deep sequencing of human
MAIT cells reveal stable oligoclonal TCRβ repertoire. Nat Commun 2014. 5:
3866.
8 Walker, L. J., Kang, Y.-H., Smith, M. O., Tharmalingham, H., Rama-
murthy, N., Fleming, V. M., Sahgal, N. et al., Human MAIT and CD8αα
cells develop from a pool of type-17 precommitted CD8+ T cells. Blood
2012. 119: 422–433.
9 Treiner, E. and Lantz, O., CD1d-and MR1-restricted invariant T cells: of
mice and men. Curr Opin Immunol 2006. 18: 519–526.
10 Tang, X.-Z., Jo, J., Tan, A. T., Sandalova, E., Chia, A., Tan, K. C., Lee, K. H.
et al., IL-7 licenses activation of human liver intrasinusoidal mucosal-
associated invariant T cells. J Immunol 2013. 190: 3142–3152.
11 Kjer-Nielsen, L., Patel, O., Corbett, A. J., Le Nours, J., Meehan, B., Liu,
L., Bhati, M. et al., MR1 presents microbial vitamin B metabolites to
MAIT cells. Nature 2012. 491: 717–723.
12 Corbett, A. J., Eckle, S. B. G., Birkinshaw, R. W., Liu, L., Patel, O.,Mahony,
J., Chen, Z. et al., T-cell activation by transitory neo-antigens derived
from distinct microbial pathways. Nature 2014. 509: 361–365.
13 Le Bourhis, L., Martin, E., Pe´guillet, I., Guihot, A., Froux, N., Core´, M.,
Le´vy, E. et al., Antimicrobial activity of mucosal-associated invariant
T cells. Nat Immunol 2010. 11: 701–708.
14 Ussher, J. E., Bilton, M., Attwod, E., Shadwell, J., Richardson, R., de Lara,
C.,Mettke, E. et al., CD161++CD8+T cells, including theMAIT cell subset,
are specifically activated by IL-12+IL-18 in a TCR-independent manner.
Eur J Immunol 2014. 44: 195–203.
15 Jo, J., Tan, A. T., Ussher, J. E., Sandalova, E., Tang, X.-Z., Tan-Garcia,
A., To, N. et al., Toll-like receptor 8 agonist and bacteria trigger potent
activation of innate immune cells in human liver. PLoS Pathog 2014. 10:
e1004210.
16 Cosgrove, C., Ussher, J. E., Rauch, A., Ga¨rtner, K., Kurioka, A., Hu¨hn,
M. H., Adelmann, K. et al., Early and nonreversible decrease of
CD161++/MAIT cells in HIV infection. Blood 2013. 121: 951–961.
17 Reantragoon, R., Kjer-Nielsen, L., Patel, O., Chen, Z., Illing, P. T., Bhati,
M., Kostenko, L. et al., Structural insight into MR1-mediated recognition
of the mucosal associated invariant T cell receptor. J Exp Med 2012. 209:
761–774.
18 Chua, W.-J., Kim, S., Myers, N., Huang, S., Yu, L., Fremont, D. H.,
Diamond, M. S. et al., Endogenous MHC-related protein 1 is tran-
siently expressed on the plasma membrane in a conformation that acti-
vates mucosal-associated invariant T cells. J Immunol 2011. 186: 4744–
4750.
19 Zhang, C., Bai, N., Chang, A., Zhang, Z., Yin, J., Shen, W., Tian, Y. et al.,
ATF4 is directly recruited by TLR4 signaling and positively regulates
TLR4-trigged cytokine production in humanmonocytes. Cell Mol Immunol
2013. 10: 84–94.
20 Haas, J. G., Baeuerle, P. A., Riethmu¨ller, G. and Ziegler-Heitbrock, H. W.,
Molecular mechanisms in downregulation of tumor necrosis factor
expression. Proc Natl Acad Sci U S A 1990. 87: 9563–9567.
21 Ziegler-Heitbrock, H. W., Blumenstein, M., Ka¨fferlein, E., Kieper, D.,
Petersmann, I., Endres, S., Flegel, W. A. et al., In vitro desensitization
to lipopolysaccharide suppresses tumour necrosis factor, interleukin-1
and interleukin-6 gene expression in a similar fashion. Immunology 1992.
75: 264–268.
22 Karp, C. L.,Wysocka, M.,Ma, X.,Marovich, M., Factor, R. E., Nutman, T.,
Armant,M. et al., Potent suppression of IL-12 production frommonocytes
and dendritic cells during endotoxin tolerance. Eur J Immunol 1998. 28:
3128–3136.
23 Lakics, V. and Vogel, S. N., Lipopolysaccharide and ceramide use diver-
gent signaling pathways to induce cell death in murine macrophages.
J Immunol 1998. 161: 2490–2500.
24 Munn, D. H., Beall, A. C., Song, D., Wrenn, R. W. and Throck-
morton, D. C., Activation-induced apoptosis in human macrophages:
C© 2016 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
1614 James E. Ussher et al. Eur. J. Immunol. 2016. 46: 1600–1614
developmental regulation of a novel cell death pathway by macrophage
colony-stimulating factor and interferon gamma. J Exp Med 1995. 181:
127–136.
25 Wolk, K.,Do¨cke,W.-D., von Baehr, V.,Volk, H.-D. and Sabat, R., Impaired
antigen presentation by human monocytes during endotoxin tolerance.
Blood 2000. 96: 218–223.
26 Huang, S., Gilfillan, S., Kim, S., Thompson, B., Wang, X., Sant, A. J., Fre-
mont, D. H., xet al., MR1 uses an endocytic pathway to activate mucosal-
associated invariant T cells. J Exp Med 2008. 205: 1201–1211.
27 Elson, G., Dunn-Siegrist, I., Daubeuf, B. and Pugin, J., Contribution of
Toll-like receptors to the innate immune response to Gram-negative and
Gram-positive bacteria. Blood 2007. 109: 1574–1583.
28 Park, O.-J., Han, J. Y., Baik, J. E., Jeon, J. H., Kang, S.-S., Yun, C.-H., Oh,
J.-W. et al., Lipoteichoic acid of Enterococcus faecalis induces the expres-
sion of chemokines via TLR2 and PAFR signaling pathways. J Leukoc Biol
2013. 94: 1275–1284.
29 van der Aar, A. M. G., Sylva-Steenland, R. M. R., Bos, J. D., Kapsen-
berg, M. L., de Jong, E. C. and Teunissen, M. B. M., Cutting edge: loss of
TLR2, TLR4, andTLR5 on Langerhans cells abolishes bacterial recognition.
J Immunol 2007. 178: 1986–1990.
30 Abtin, A., Eckhart, L., Mildner, M., Gruber, F., Schro¨der, J.-M. and
Tschachler, E., Flagellin is the principal inducer of the antimicrobial pep-
tide S100A7c (psoriasin) in human epidermal keratinocytes exposed to
Escherichia coli. FASEB J 2008. 22: 2168–2176.
31 Mattsby-Baltzer, I., Lindgren, K., Lindholm, B. and Edebo, L., Endotoxin
shedding by enterobacteria: free and cell-bound endotoxin differ in Limu-
lus activity. Infect Immun 1991. 59: 689–695.
32 Erridge, C., Lysozyme promotes the release of toll-like receptor-2 stimu-
lants from gram-positive but not gram-negative intestinal bacteria. Gut
Microbes 2010. 1: 383–387.
33 Riegert, P.,Wanner, V. and Bahram, S., Genomics, isoforms, expression,
and phylogeny of the MHC class I-related MR1 gene. J Immunol 1998. 161:
4066–4077.
34 Gold, M. C., Cerri, S., Smyk-Pearson, S., Cansler, M. E., Vogt, T. M.,
Delepine, J.,Winata, E. et al., Humanmucosal associated invariant T cells
detect bacterially infected cells. PLoS Biol 2010. 8: e1000407.
35 Turtle, C. J.,Delrow, J., Joslyn, R. C., Swanson, H. M., Basom, R., Tabellini,
L., Delaney, C. et al., Innate signals overcome acquired TCR signaling
pathway regulation and govern the fate of human CD161hi CD8α+ semi-
invariant T cells. Blood 2011. 118: 2752–2762.
36 Biswas, S. K. and Lopez-Collazo, E., Endotoxin tolerance: new mecha-
nisms, molecules and clinical significance. Trends Immunol. 30: 475–487.
37 Liew, F. Y., Xu, D., Brint, E. K. and O’Neill, L. A. J., Negative regulation of
Toll-like receptor-mediated immune responses. Nat Rev Immunol 2005. 5:
446–458.
38 Haase, R.,Kirschning, C. J., Sing, A., Schro¨ttner, P., Fukase, K.,Kusumoto,
S., Wagner, H. et al., A dominant role of Toll-like receptor 4 in the sig-
naling of apoptosis in bacteria-faced macrophages. J Immunol 2003. 171:
4294–4303.
39 Kloverpris, H. N., Stryhn, A., Harndahl, M., van der Stok, M., Payne, R. P.,
Matthews, P. C., Chen, F. et al., HLA-B* 57 micropolymorphism shapes
HLA allele-specific epitope immunogenicity, selection pressure, and HIV
immune control. J Virol 2012. 86: 919–929.
40 Buchwalow, I. B. and Bo¨cker, W., Immunohistochemistry: basics and meth-
ods. Springer Berlin Heidelberg: 2010.
41 Brown, J. K., Pemberton, A. D., Wright, S. H. and Miller, H. R. P., Primary
antibody–Fab fragment complexes: a flexible alternative to traditional
direct and indirect immunolabeling techniques. J Histochem Cytochem
2004. 52: 1219–1230.
Abbreviations: APC: antigen presenting cell · MAIT cells: mucosal-
associated invariant T-cells · MDM: monocyte-derived macrophage
Full correspondence: James E. Ussher, Department of Microbiology and
Immunology, University of Otago, PO Box 56, Dunedin 9054,
New Zealand
Fax: +64-3-479-8540
e-mail: james.ussher@otago.ac.nz
Received: 1/8/2015
Revised: 27/2/2016
Accepted: 18/4/2016
Accepted article online: 23/4/2016
C© 2016 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
